The upcoming market report contains data for the historical year 2015, the base year of calculation is 2016 and the forecast period is 2017 to 2024. The https://marketreports.co/global-infectious-immunology-market-size-status-and-forecast-2019-2025/171459/#Free-Sample-Report

The report offers information of the market segmentation by type, application, and regions in general. The report highlights the development policies and plans, government regulations, manufacturing processes, and cost structures. It also covers technical data, manufacturing plants analysis, and raw material sources analysis as well as explains which product has the highest penetration, their profit margins, and R&D status.

Read Detailed Index of full Research Study at @ https://marketreports.co/global-infectious-immunology-market-size-status-and-forecast-2019-2025/171459/

The Top Key players Of Global Infectious Immunology Market:

Types of Global Infectious Immunology Market:

Applications Of Global Infectious Immunology Market:

Regional Segmentation for Infectious Immunology market:

Table of Content (TOC) at a glance:Overview of the market includes Definition, Specifications, and Classification of Infectious Immunology Size, Features, Scope, and Applications.

Product Cost and Pricing Analysis: The Manufacturing Cost Structure, Raw Material, and Suppliers cost, Manufacturing Process, Industry Chain Structure.

Market Demand and Supply Analysis that includes, Capacity and Commercial Production Date, Manufacturing Plants Distribution, R&D Status and Technology Source, Raw Materials Sources Analysis;Forces that drive the market

In the end, the report covers the precisely studied and evaluated data of the global market players and their scope in the market using a number of analytical tools. The analytical tools such as investment return analysis, SWOT analysis, and feasibility study are used to analyses the key global market players growth in the Infectious Immunology.

Check here for the [emailprotected]https://marketreports.co/global-infectious-immunology-market-size-status-and-forecast-2019-2025/171459/#Buying-Enquiry

Customization of the Report:This report can be customized to meet the clients requirements. Please connect with our sales team ([emailprotected]), who will ensure that you get a report that suits your needs.

Here is the original post:
Infectious Immunology Market 2019, Trend, CAGR Status, Growth, Analysis and Forecast to 2025 - VaporBlash

Scientists at Scripps Research have developed a method for rapidly discovering potential cancer-treating compounds that work by resurrecting anti-tumor activity in immune cells called T cells.

Cancerous tumors often thrive because they render T cells dysfunctional or exhausted. The new method uncovers medicinal compounds that can restore the function of these T cells, making cancers vulnerable to them again.

The approach, described in a studypublished inCell Reports, may also help restore T-cell responses to persistent infections from viruses or other pathogens. It therefore should speed the development of new cancer and infectious-disease immunotherapies, including those that can be combined with existing immunotherapy drugs to enhance their effects. The scientists demonstrated the potential utility of the approach by using it to rapidly screen a collection of more than 12,000 drug compoundsuncovering 19 that can reawaken exhausted T cells.

This new screening method should be particularly useful because we can use it not only to identify compounds that restore needed function to exhausted T cells, but also to quickly analyze these T cells to determine how these compounds work on them, says senior authorMichael Oldstone, MD, Professor Emeritus in the Department of Immunology and Microbiology at Scripps Research.

The new screening systemand to some extent, the wider field of cancer immunotherapyis based in part on research over the past several decades by Oldstones laboratory and several former lab members including Rafi Ahmed, David Brooks, and John Teijaro, along with other scientists that have conducted animal-based research on how the immune system responds to lymphocytic choriomeningitis virus (LCMV).

A unique variant of LCMV known as clone 13 establishes a persistent infection by exhausting the virus-specific T cells that are required to clear the infection. It does this by boosting signals through T-cell receptors such as PD-1 and IL-10. The discovery that LCMV clone 13 can survive by switching off anti-LCMV T cells was quickly followed by the recognition that cancers often persist using the same trick.

Immunotherapies that block signaling from PD-1 or similarly acting receptors to restore T cells anti-cancer responses are among the most powerful cancer medicines available today. These therapies save many patients who in the past had seemingly untreatable tumors. But because treatment with these drugs typically works well for only a few cancers, including melanomaand less often on other cancersscientists suspect that cancers usually hijack multiple inhibitory T-cell pathways. This suggests that a combination of immunotherapies directed to different molecular pathways could be more effective than the current therapy.

The idea now is to develop more immunotherapy drugs and find the best combinations of them, Oldstone says.

A promising hit

The new screening system is designed to enable scientists to swiftly find such drugsin this case, pharmacologically active small-molecule compounds that might work better than, or augment, the current injectable antibody immunotherapies now available.

The system uses T cells that have been exhausted by LCMV clone 13 and detects signs of renewed activity in these cells when a tested compound works to reawaken them. An advantage of the new screening system is that it is specific and highly automated; thus, thousands of compounds can be tested within days, with the hits verified in experiments involving mice.

Oldstone and colleagues applied the new screening system to adrug repurposing libraryof more than 12,000 compounds that either are FDA-approved or have been tested as potential drugs. They quickly identified 19 hitscompounds that, at modest doses, can effectively resurrect the activity of exhausted T cells.

One of these compounds, ingenol mebutate, is a plant-derived molecule that is already used in gel form (Picato) to treat actinic keratosis, a pre-cancerous skin condition. The researchers employed elements of their screening system to study the reactivated T cells and determined that ingenol mebutate restores function for these cells largely by activating signaling enzymes called protein kinase C enzymes, a known pathway of activity for this compound.

Co-first authors of the study, postdoctoral fellows Brett Marro, PhD and Jaroslav Zak, PhD, in the Department of Immunology and Microbiology, are currently collecting and exploring the therapeutic potential of other reported hits that may work in combination with treatments that block PD-1- and another T-cell-inhibitory receptor, CTLA-4. Indeed, one such hit in combination with antibody to PD-L1 is already undergoing evaluation in patients.

Oldstone notes that the new screening approach is flexible enough to adapt for finding compounds that have other effects on T-cells, such as reducing T-cell activity to treat autoimmune conditions.

Reference: Marro, et al. (2019) Discovery of Small Molecules for the Reversal of T Cell Exhaustion. Cell Reports. DOI:https://doi.org/10.1016/j.celrep.2019.10.119

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.

More:
Detecting Potential Anticancer Compounds That Reawaken T Cells - Technology Networks

Aqilion is strengthening its portfolio with the addition of two innovative preclinical projects, Alhena and Alnitak. The company is overseeing the two pharmaceutical projects, which both fall under Aqilions new focus area: inflammation at the interface of oncology and immunology.

The Alhena project aims to develop a PROTAC drug against a target protein that is central to some cancers. PROTAC is an acronym for proteolysis-targeting chimera (PROTAC). Basically, the technology uses the cells own system to break down a certain target protein in the cell, instead of just trying to block its action. The Alhena project involves combination therapy in immuno-oncology with an initial focus on aggressive, treatment-resistant triple negative breast cancer.

The Alnitak project has two interesting applications. The goal is to develop drug candidates that bind to a target protein that is essential for both malignant disease development and for inflammatory conditions. A successful project can therefore help to develop new medications to treat orphan drug indications in the field of autoinflammatory diseases, as well as new combination therapies within the field of oncology, primarily intestinal cancer.

Aqilion oversees both projects in collaboration with selected contract research organizations (CROs) specializing in innovative early pharmaceutical projects. The objective is to develop both projects into attractive preclinical projects and then identify a partner for the clinical and commercial development.

We are proud to announce that Aqilion is now launching two innovative pharmaceutical projects that are both based on new knowledge from the pharmaceutical industry and academic research in the fields of oncology, inflammation and immunology. I am convinced that our new area of focus and approach will result in synergies, greater knowledge within the team and strong collaboration in the future with selected partners and customers in industry. I look forward to reporting the results moving forward, says Sarah Fredriksson, CEO of AQILION AB.

Aqilion is in a transitional phase that has entailed a new start based on solid analysis and culminating in a forward-looking strategy. Earlier this year, the company changed its name to Aqilion in acknowledgement of this transition. The path has included recruitment of a strengthened team, as well as an inventory and validation of the projects Aqilion had in its portfolio at that time. Willingness to build a business model that delivers, combined with the courage to discontinue those projects that do not meet set criteria, will be crucial to its success.

For more information, please contactSarah Fredriksson, CEO, AQILION AB, +46 (0)70 261 4575, sarah.fredriksson@aqilion.com

About AQILION ABAqilion is a Swedish life science company that identifies unique pharmaceutical projects at an early phase in the drug discovery process and develops them in preparation for clinical trials. The goal is to demonstrate the clinical and commercial potential of the medical innovation to attract industrial partners and buyers, who in turn have the capacity to continue clinical development and take the product to market. The business model is based on involvement at an early stage and close collaboration with the innovator, regardless of whether the project is initiated by an external researcher, internal development project, or industrial partner. Aqilion prefers projects aimed at niche markets. Specialty medications and orphan drugs are of particular interest. Aqilion has its headquarters in Helsingborg. Please visit http://www.aqilion.com.

Read the rest here:
Aqilion strengthens its portfolio with two innovative pharmaceutical projects in the fields of inflammation and oncology - PharmiWeb.com

SOUTH SAN FRANCISCO, Calif., Dec. 04, 2019 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage immunology-based biopharmaceutical companyfocused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases, today announced the appointment of Rodney Young as chief financial officer effective December 2, 2019.

As a newly public company, we are thrilled to welcome Rodney to RAPT, said Brian Wong, M.D., Ph.D., president and CEO of RAPT Therapeutics. He is a seasoned executive who brings broad strategic, operational and financial expertise to help biotech companies grow successfully. Rodney will lead our finance and administrative functions and work closely with the executive team to guide the companys development across all operational areas.

Mr. Young brings more than 30 years of executive management and corporate finance experience. Most recently, he served as chief financial officer of Cellerant Therapeutics, Inc., a private clinical-stage company developing cell and antibody-based immunotherapies for blood cancers and related disorders, where he was responsible for accounting and financial management, and played a key role in determining corporate strategy. Previously, he served as chief financial officer and vice president of finance and administration of StemCells, Inc., a public biotechnology company developing stem cell therapeutics for central nervous system disorders, where he was responsible for raising over $200 million in financing. Earlier in his career, he was an investment banker at Lehman Brothers and SG Cowen, leading financing and merger and acquisition transactions focused in the healthcare, biotechnology, and pharmaceutical sectors. Mr. Young received his MBA and BA from the University of Chicago.

RAPT has a compelling drug discovery platform that has generated promising therapeutic drug candidates, said Mr. Young. With an experienced team and thoughtful clinical development plans, RAPT expects to have data from two compounds reading out in 2020. Im thrilled to join the company at this important time.

About RAPT Therapeutics, Inc.

RAPT Therapeutics (formerly FLX Bio) is a clinical stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases. Utilizing its proprietary discovery and development engine, the company is developing highly selective small molecules designed to modulate the critical immune responses underlying these diseases. In its first four years since inception, RAPT has discovered and advanced two unique drug candidates, each targeting C-C motif chemokine receptor 4. The companys lead oncology drug candidate, FLX475, reached the clinic in just two and a half years and RPT193, its lead inflammation drug candidate, is also in the clinic. The company is also pursuing a range of targets, including general control nonderepressible 2 and hematopoietic progenitor kinase 1, that are in the discovery stage of development.

Media Contact:Angela Bittingmedia@rapt.com(925) 202-6211

Investor Contact:Sylvia Wheelerswheeler@wheelhouselsa.com

View post:
RAPT Therapeutics Appoints Rodney Young as Chief Financial Officer - BioSpace

Research indicates that approximately 1 in 3,000 hospitalized patients suffer drug-induced anaphylaxis. Previous studies investigating anaphylaxis epidemiology used billing codes to broadly determine causes of these life-threatening allergic reactions (eg, drug, food, and venom) but lacked information on specific causative drugs or drug classes. Large-scale studies using EHR allergy lists to describe drug allergy have been infrequent.

At Partners Healthcare System, patient allergy information captured by the EHR allergy module was integrated into the Partners enterprise-wide allergy repository (PEAR), resulting in a longitudinal allergy record accessible across the healthcare network. For a study published in The Journal of Allergy and Clinical Immunology: In Practice, my colleagues and I used drug allergy data of patients who visited Brigham and Womens Hospital and Massachusetts General Hospital between 1995 and 2013 to determine the population prevalence of anaphylaxis, including anaphylaxis prevalence over time and the most commonly implicated drugs/drug classes reported to cause anaphylaxis.

Among approximately 1.8 million patients, 1.1% reported drug-induced anaphylaxis. Penicillins (45.9 per 10,000), sulfonamide antibiotics (15.1 per 10,000), and NSAIDs (13.0 per 10,000) were most commonly implicated. Female gender, Caucasian race, systemic mastocytosis, Sjgrens syndrome, asthma, and COPD were risk factors for anaphylaxis. We found that serum tryptase was tested in less than 1% of anaphylaxis cases at any time (33% of tests ordered during the correct time window), and only 8% visited an allergist for follow-up during the study period (1.4% within 30 days of anaphylaxis).

The patient-specific risk factors noted above can be used clinically in discussion with patients about drug-induced anaphylaxis. Our findings also emphasize the need to improve the verification of EHR-reported anaphylaxis with tryptase testing and subsequent allergist evaluation.

Drug-Induced Anaphylaxis Documented in Electronic Health Recordshttps://www.jaci-inpractice.org/article/S2213-2198(18)30411-2/abstract

Read the original here:
Assessing Drug-Induced Anaphylaxis - Physician's Weekly

BUFFALO GROVE, Ill.--(BUSINESS WIRE)--Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today multiple executive appointments. As previously announced as part of the Companys succession plan, Terrie Curran, former President of the Global Inflammation and Immunology (I&I) Franchise at Celgene, now joins Phathom as Chief Executive Officer. Founding CEO David Socks transitions to interim Chief Financial Officer and remains a member of the Board of Directors. In addition to Ms. Curran, also joining the Phathom leadership team are Eckhard Leifke, MD, as Chief Medical Officer; Joseph Hand, JD, as Chief Administrative Officer; and Larry Miller, JD, as General Counsel. Phathom also announced today that Asit Parikh, MD, PhD has replaced Chris Slavinsky on the Companys Board of Directors.

I am thrilled to be joining Phathom at this exciting time, as vonoprazan, our product candidate for the treatment of acid-related disorders, moves into Phase 3 clinical trials in multiple indications, said Ms. Curran. I look forward to continuing to work with David, along with our expanded leadership team, to bring this important and novel therapy to underserved patients. I am also very pleased with our ability to attract exceptionally talented and experienced leaders such as Eckhard, Joe, and Larry as we continue to build the Company.

Ms. Curran has more than 20 years of experience in the biopharmaceutical industry. She has served as President, Global Inflammation and Immunology (I&I) Franchise and as a member of the Executive Committee at Celgene Corporation since 2017. Ms. Curran joined Celgene in 2013 as the U.S. Commercial Head of the I&I Franchise and built the capabilities and recruited the teams that executed the successful launch of OTEZLA, which was sold to Amgen in November 2019 for $13.4 billion. Prior to joining Celgene, she served as Senior Vice President and General Manager, Global Womens Health at Merck & Co. She currently serves on the board of Myovant Sciences and previously served on the board of H. Lundbeck A/S. Ms. Curran holds graduate and bachelors degrees from the University of Technology, Sydney.

Dr. Leifke joins Phathom from Omeros where he served as Chief Medical Officer. Prior to Omeros, he held executive roles at Sanofi, including Global Head/Vice President of Early Project & External Opportunities - Cardiovascular and Metabolism and Global Head/Vice President of Late Stage Development - Diabetes. Dr. Leifke has built global teams at pharmaceutical companies including Bayer and Takeda and led the global development of multiple early- and late-stage small molecule and biologic drug candidates to successful marketing authorizations worldwide. Dr. Leifke holds an MD from the University of Freiburg, Germany and is board-certified in internal medicine and endocrinology.

Mr. Hand joins Phathom from Celgene, where he most recently served as Executive Vice President, Global Human Resources and Corporate Services and a member of its Executive Committee. In that capacity, he was responsible for all employee-related activities including talent development, recruiting, and compensation and benefits. He was also responsible for the management of Celgenes global facilities footprint. Prior to Celgene, he was a litigation attorney at the international law firm of Jones Day. Mr. Hand holds a BBA from the University of Notre Dame and a JD from New York University School of Law.

Mr. Miller joins Phathom as General Counsel from Cyclerion Therapeutics where he served as General Counsel and Secretary. Prior to Cyclerion, he served as Senior Vice President, General Counsel and Secretary of Blue Buffalo where he led all legal activities including those related to the $8 billion acquisition by General Mills. Mr. Miller has also served as Chief Counsel for Pfizer Consumer Healthcare, Chief Counsel for the Pfizer Established Products Business Unit, and General Counsel of Enzon Pharmaceuticals. He holds an AB from Dartmouth College and a JD from Columbia University School of Law.

In addition to the executive appointments, Dr. Parikh joins Phathoms Board of Directors as Chris Slavinsky steps down following his departure from Takeda to join Prometheus Biosciences. Dr. Parikh is currently Senior Vice President and Head of the Gastroenterology Therapeutic Area Unit at Takeda. He brings to Phathoms Board significant gastrointestinal therapeutic area experience, including the global development of Entyvio and Takedas other gastroenterology programs. Dr. Parikh earned his PhD in Biochemistry and MD from Vanderbilt University and completed his internal medicine residency at the University of Pennsylvania. He also completed subspecialty training in gastroenterology at the Massachusetts General Hospital and postdoctoral work in cancer biology at MIT.

I look forward to working with Asit and expect his deep gastroenterology drug development experience will be a tremendous asset to Phathom, said Tadataka (Tachi) Yamada, MD, Chairman of the Board at Phathom. I would also like to extend my sincere thanks to Chris for his instrumental role in shaping Phathom from its inception.

About Phathom

Phathom Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases and disorders. Phathom has licensed the exclusive rights in the United States, Europe, and Canada to vonoprazan, a novel potassium competitive acid blocker (P-CAB) in late-stage development for the treatment of acid-related disorders. For more information about Phathom, visit the Companys website at http://www.phathompharma.com.

Forward Looking Statements

The Company cautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking statements. These statements are based on the companys current beliefs and expectations. Such forward-looking statements include, but are not limited to, statements regarding vonoprazan moving into and potential success in the Companys Phase 3 clinical trials and the effect of the Companys planned management transition. The inclusion of forward-looking statements should not be regarded as a representation by the Company that any of its plans will be achieved. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in the Companys business, including, without limitation: the Companys ability to recruit patients for Phase 3 clinical trials; the potential for negative clinical trial results; reliance on third parties for manufacturing and certain development efforts; challenges in integrating new members of the management team and board of directors; and the need to continue to attract, integrate, retain and motivate necessary personnel to accomplish the Companys business objectives, as well as other risks described in the companys prior press releases and the Companys filings with the Securities and Exchange Commission (SEC), including under the heading Risk Factors in the Companys Registration Statement on Form S-1 and any subsequent filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Phathom undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

Continued here:
Phathom Pharmaceuticals Expands Leadership Team and Announces Board Transition - Business Wire

Its pipeline priming time at IFM Therapeutics. And they have the money to get the job done.

The immunology experts at the discovery outfit have lined up $55.5 million in new venture backing from an expanded syndicate still including their big believers at Atlas. And its not hard to figure out the motivation.

Gary Glick, whos moving from CEO to executive chairman on this round, and his team have lined up a slate of deals for their early-stage work.

Just 2 months ago Novartiss NIBR stepped up with an $840 million buyout option tied to research funding for therapeutics that fire up the STING pathway. And theyve reaped more than $600 million in cash from Bristol-Myers and Novartis on both sides of NLRP3, tamping down as well as triggering that pathway, in addition to STING.

The financing will have a goal of graduating 2 programs into subsidiaries, says Martin Seidel, a NIBR vet whos now moving up to the CEO post after running research for IFM over the last couple of years.

Now comes their third subsidiary, IFM Quattro, as the crew also starts their own incubator to play with some new ideas in the field.

Theyre sticking to their area of expertise in the innate immune system, looking for new ways that work in fighting cancer as well as new anti-inflammatories. What exactly is on the horizon is a topic they arent ready to discuss with Endpoints News, but there are a variety of possibilities. Just a couple of weeks ago a group of their scientists and collaborators published new work on the role the inflammasome plays in tau pathology a possible new approach to Alzheimers, where nothing has worked so far.

So the plan at a high level is to continue to execute on the strategy: Take target specific programs into subsidiaries and then hunt up partners around the IND stage, says Lina Gugucheva, the BD chief at IFM. The new venture round will be enough to fuel the company of 35 staffers for the next 3 years or so as it sets up the new subsidiaries and starts to look to execute new deals.

With their track record, backers have good reason to believe that IFM has decent odds of paying off again with a solid multiple in a relatively short span of time. As a result, says Glick, there was plenty of interest from new investors, and they opted to let Omega Funds into the small syndicate, alongside Atlas and Abingworth. Omegas Paulina Hill joins Jean-Francois Formela at Atlas and Shelley Chu from Abingworth on the board.

So whats with the Italian numbering system at IFM? Glick says it was inspired by a traditional 12 course Italian meal. And that leaves IFM preparing the main course.

Social image: Martin Seidel, Gary Glick, Lina Gugucheva

Read more:
Numero quattro: Immunology experts at deal-focused IFM line up $55.5M for the next leg of their drug exploration journey - Endpoints News

By Michelle Morgante, UC Merced

The annual Give Tue UC Merced campaign takes place on Tuesday, Dec. 3.

Jose Nava-Mejia hopes to work in renewable energy after he graduates from UC Merced. That means every moment spent on his environmental energy courses is a moment invested in the planets future.

Kelsey Duggin hopes to use her microbiology and immunology studies to become a virologist and work with stem cells. Vania Huaranga plans to become a neuropsychologist.

The three are among the scores of UC Merced undergraduates whose studies are backed by the Build the Future Scholarship Fund, which is supported by donations collected during Give Tue UC Merced.

The annual day of giving campaign takes place Tuesday, Dec. 3. During the 24 hours of worldwide Giving Tuesday, UC Merced has set a goal of drawing gifts from 1,000 donors.

Donations designated for the Build the Future Scholarship Fund will be matched 3-to-1 by Foster Poultry Farms, quadrupling the impact of every dollar.

In addition, donors can support UC Merceds Graduate Student Fellowship Fund. The first 100 donations to the fund will be amplified by a matching donation that will provide up to $1,000 from longtime campus friends Dr. Robert Bernstein and Dr. Jane Binger. Vice Provost and Graduate Dean Marjorie Zatz is offering a similar match.

This years Give Tue UC Merced marks the sixth year of the campaign.

Support from the gifts made during Give Tue UC Merced transforms the lives of our students, their families and their communities, interim Chancellor Nathan Brostrom said. Every donation helps us build a better future by supporting the education of the next generation of world-class researchers.

Nava-Mejia, a 19-year-old first-generation student from Merced, said the Build the Future Scholarship allows him to devote more time to his studies.

It means a lot because I can focus on my education, he said. With the scholarship, I can pay for my books and transportation costs. It also lifts a burden off my parents.

UC Merced is a national leader in student outcomes and social mobility, with nine out of 10 students receiving some form of financial assistance. Such financial support was one of the main reasons Duggin decided to enroll.

The support from the Build the Future Scholarship has provided me with the ability to pay for all of the basic necessities, said the second-year student from La Crescenta. It gave me reassurance that hard-working students are rewarded and it motivates me to continue to prioritize my studies.

For Huaranga, a first-year psychology major from Antioch, the Build the Future Scholarship not only provides financial backing, it helps her feel supported as she transitions into college life.

"As a first-generation student, college tuition can be very costly for our families," she said. The Build the Future Scholarship has been very significant to me for many reasons but my main reason is that it gave me a sense that there are people out there who support students. This made me feel that I am not alone and that there are people who believe in me.

"Support from the gifts made during Give Tue UC Merced transforms the lives of our students, their families and their communities.

Last year, the Give Tue UC Merced campaign raised more than $170,000, bringing the total collected over the past five years to more than $1.5 million.

Currently, 144 students are receiving support from the Build the Future Scholarship. And thanks to the generosity of Foster Poultry Farms, there will be a 3-to-1 match on gifts made to the Build the Future Scholarship Fund, up to a total of $100,000 during Give Tue UC Merced.

Online gifts can be directed to givetue.ucmerced.edu ; Donations also will be collected at locations across campus on Tuesday, Dec. 3.

Numerous events will be held on campus throughout the day to raise awareness of Give Tue UC Merced and support a culture of giving back. Housing and Residence Life is organizing a Dollars for Scholars carnival event, including a chance for donors to toss pies at resident assistants and a holiday social featuring an ugly sweater contest. The events are open to all students and a $1 donation is encouraged.

The Graduate Division will offer coffee and churros to donors Tuesday afternoon.

Last year marked the second year in which the campus met its 1,000-donor goal on Give Tue UC Merced. Those donors included nearly 500 students, underscoring a growing tradition of giving among Bobcats.

Huaranga said receiving support from the Build the Future Scholarship has inspired her to want to, in the future, give scholarships that will help students from her hometown attend UC Merced.

Duggin said she also hopes to contribute to the university.

I hope to eventually be able to give back to UC Merced, specifically to benefit the students. I want the future generations to have access to a great education without worrying about finances, Duggin said. Give Tue UC Merced is a great event that allows donors to support the school and the students. Thank you to the donors who invest in the students at UC Merced it really makes a difference.

Continue reading here:
UC Merced Aims to Draw 1,000 Donors in a Day with 'Give Tue UC Merced' Campaign | Newsroom - UC Merced University News

GRAND JUNCTION, Colo. (KJCT) - If youre finding yourself sniffling this time of year, youre not alone.

According to Mayo Clinic, more than 16 million Americans suffer from Winter Allergies. This irritation can be caused by regular indoor offenders but your holiday centerpiece might also be to blame. Its often not the Christmas trees themselves but the mold that grows on it.

If you really get your head in there and inhale a lot of that particulate matter from the tree, that can really put people into a few days of sinus congestion, sometimes even lead to sinusitis, says Allergy and Immunology Specialist David Scott, M.D.

Expert recommend keeping your tree in a well-ventilated area.

Read the original here:
Winter allergies and your Christmas tree - KJCT8.com

Infectious Immunology Market 2024:

The global Infectious Immunology market report added by Alexa Report is based on the year 2019. This market report studies Manufacturers (including international and domestic), Suppliers and Vendors, Regions, Product Type, Product Variants and Application for the forecast period. The study provides information on past and present market trends and development, drivers, capacities, technologies, and on the changing capital structure of the Infectious Immunology Market. The study will help the market players and consultants to understand the on-going structure of the market.

Request your Sample PDF Report: @ https://www.alexareports.com/report-sample/188749

The report provides a basic overview of the industry including definition, applications and classifications. Then, the report explores the international and regional major industry players in detail. The overview covered in this report also presents the company profile, product specifications, capacity, production value, and market shares for each company.

The key regions in the market which have a scope of development and a large number of opportunities in the Infectious Immunology Market have been provided thoroughly studied in this report.

This research study involved the extensive use of both primary and secondary data sources. The research process involved the study of dynamic factors affecting the industry such as the government policy, market environment, competitive landscape, historical data, present trends in the market, technological innovations, upcoming technologies and the technical progress in industry.

Prominent players ruling the industry

Some of the key players operating in the market are Abbott Laboratories, Roche Diagnostics, Thermo Fisher Scientifics, Bio-Rad Laboratories, Dr. Reddys Laboratories.

Segmentation of Infectious Immunology Market:

By Application, are HIV, TB, HBV and HCV, Pneumonia, Malaria

Grab amazing discount [emailprotected] https://www.alexareports.com/check-discount/188749

The objective of the reports:The report offers information of the market segmentation by type, application and regions in general. The report highlights the development policies and plans, government regulations, manufacturing processes and cost structures. It also covers technical data, manufacturing plants analysis, and raw material sources analysis as well as explains which product has the highest penetration, their profit margins, and R&D status. Infectious Immunology market analysis further consists of a competitive landscape of Infectious Immunology market, market development history and major development trends.

Table of Content (TOC) at a glance:Chapter 1, Overview of the market includes Definition, Specifications and Classification of Infectious Immunology market, Features, Scope, and Applications.Chapter 2, Product Cost and Pricing Analysis: The Manufacturing Cost Structure, Raw Material and Suppliers cost, Manufacturing Process, Industry Chain Structure.Chapter 3, Market Demand and Supply Analysis that includes, Capacity and Commercial Production Date, Manufacturing Plants Distribution, R&D Status and Technology Source, Raw Materials Sources Analysis;Chapter 4, Forces that drive the marketChapter 5 and 6, Regional Market Analysis that includes North America, Europe, China, Japan, Southeast Asia & India, Infectious Immunology Market Analysis (by Type);Chapter 7 and 8, Industrial structureChapter 9, Market Trend Analysis, Regional Market Trend, Market Trend by Product TypeChapter 10, Infectious Immunology sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source.

To Enquire About This Comprehensive Report, Click Here: https://www.alexareports.com/send-an-enquiry/188749

In the end, the report covers the precisely studied and evaluated data of the global market players and their scope in the market using a number of analytical tools. The analytical tools such as investment return analysis, SWOT analysis, and feasibility study are used to analyze the key global market players growth in the Infectious Immunology industry.

About Us:Alexa Reports is a globally celebrated premium market research service provider, with a strong legacy of empowering business with years of experience. We help our clients by implementing decision support system through progressive statistical surveying, in-depth market analysis, and reliable forecast data. Alexa Reports is a globally celebrated premium market research service provider, with a strong legacy of empowering business with years of experience. We help our clients by implementing decision support system through progressive statistical surveying, in-depth market analysis, and reliable forecast data.

Contact Us:Alexa ReportsPh no: +1-408-844-4624 / +91- 7030626939Email: [emailprotected]Site: https://www.alexareports.com

See the original post here:
Infectious Immunology Market: Overview and Forecast Application | 2019-2025 - Montana Ledger